Chromosomal instability (CIN) is a hallmark of human cancer, and it is associated with poor
prognosis, metastasis, and therapeutic resistance. CIN results from errors in chromosome …

Prostate cancers are considered to be immunologically 'cold'tumors given the very few
patients who respond to checkpoint inhibitor (CPI) therapy. Recently, enrichment of …

DNA methylation inhibitors have become the mainstay for treatment of certain
haematological malignancies. In addition to their abilities to reactivate genes, including …

Loss of MHC class I (MHC-I) antigen presentation in cancer cells can elicit immunotherapy
resistance. A genome-wide CRISPR/Cas9 screen identified an evolutionarily conserved …

Despite impressive durable responses, immune checkpoint inhibitors do not provide a long-
term benefit to the majority of patients with cancer. Understanding genomic correlates of …

Immune checkpoint blockade (ICB) immunotherapy is a first-line treatment for selected
cancers, yet the mechanisms of its efficacy remain incompletely understood. Furthermore …

KRAS-driven lung cancers frequently inactivate TP53 and/or STK11/LKB1, defining tumor
subclasses with emerging clinical relevance. Specifically, KRAS-LKB1 (KL)–mutant lung …

Interferon-induced transmembrane proteins (IFITMs) are broad spectrum antiviral factors that
inhibit the entry of a wide range of clinically important pathogens including influenza A virus …

Features of the cancer epigenome distinguish cancers from their respective cell of origin and
establish therapeutic vulnerabilities that can be exploited through pharmacologic inhibition …

Immunotherapy has had a tremendous impact on cancer treatment in the past decade, with
hitherto unseen responses at advanced and metastatic stages of the disease. However, the …